Los Angeles Capital Management LLC Invests $1.15 Million in Arvinas, Inc. (NASDAQ:ARVN)

Los Angeles Capital Management LLC bought a new stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 27,889 shares of the company's stock, valued at approximately $1,148,000. Los Angeles Capital Management LLC owned 0.05% of Arvinas at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. FMR LLC grew its position in shares of Arvinas by 10.6% during the third quarter. FMR LLC now owns 4,868,295 shares of the company's stock worth $95,613,000 after buying an additional 466,667 shares in the last quarter. Vanguard Group Inc. grew its holdings in Arvinas by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 4,608,223 shares of the company's stock worth $90,505,000 after acquiring an additional 90,426 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Arvinas by 18.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 429,990 shares of the company's stock worth $8,445,000 after purchasing an additional 66,430 shares during the last quarter. Algert Global LLC increased its position in shares of Arvinas by 45.5% in the 3rd quarter. Algert Global LLC now owns 173,418 shares of the company's stock worth $3,406,000 after purchasing an additional 54,229 shares during the last quarter. Finally, Federated Hermes Inc. raised its stake in shares of Arvinas by 32.4% in the 4th quarter. Federated Hermes Inc. now owns 138,028 shares of the company's stock valued at $5,681,000 after purchasing an additional 33,770 shares in the last quarter. 95.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ARVN has been the subject of several research analyst reports. Oppenheimer reissued an "outperform" rating and issued a $80.00 price objective (down from $95.00) on shares of Arvinas in a report on Wednesday, February 28th. Barclays boosted their price objective on Arvinas from $26.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, February 29th. Leerink Partnrs reaffirmed an "outperform" rating on shares of Arvinas in a research note on Thursday, February 22nd. The Goldman Sachs Group began coverage on Arvinas in a research note on Thursday, February 1st. They issued a "buy" rating and a $70.00 price target for the company. Finally, Truist Financial reaffirmed a "buy" rating and issued a $65.00 price objective on shares of Arvinas in a report on Monday, March 25th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, Arvinas currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.13.

Arvinas Stock Performance

Shares of Arvinas stock traded down $0.42 during trading on Thursday, hitting $31.95. 426,276 shares of the stock traded hands, compared to its average volume of 719,843. The company has a fifty day moving average price of $38.72 and a two-hundred day moving average price of $35.53. Arvinas, Inc. has a twelve month low of $13.57 and a twelve month high of $53.08. The stock has a market cap of $2.18 billion, a P/E ratio of -5.39 and a beta of 1.95.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.45. Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. The company had revenue of $25.30 million for the quarter, compared to analyst estimates of $32.94 million. During the same quarter in the prior year, the business posted ($1.54) EPS. Arvinas's quarterly revenue was down 22.2% on a year-over-year basis. On average, equities research analysts expect that Arvinas, Inc. will post -5.02 EPS for the current fiscal year.

Insider Activity at Arvinas

In other news, CEO John G. Houston sold 5,196 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $244,471.80. Following the completion of the sale, the chief executive officer now directly owns 1,036,681 shares in the company, valued at $48,775,841.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO John G. Houston sold 5,196 shares of the firm's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $244,471.80. Following the sale, the chief executive officer now directly owns 1,036,681 shares of the company's stock, valued at $48,775,841.05. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Sean A. Cassidy sold 1,702 shares of the business's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $80,079.10. Following the transaction, the chief financial officer now directly owns 181,916 shares of the company's stock, valued at approximately $8,559,147.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,597 shares of company stock valued at $404,489. Corporate insiders own 5.23% of the company's stock.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.